Form 4: Cytek Biosciences CEO Wenbin Jiang Reports Stock Transactions
SEC Form 4 Filing
Wenbin Jiang, CEO of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 11, 2024, Wenbin Jiang, the CEO of Cytek Biosciences, had 15,708 Restricted Stock Units (RSUs) vest.
- These RSUs converted into common stock.
- A portion of the shares (4,646) were withheld by Cytek Biosciences to cover tax obligations at a price of $7.22 per share.
- Following these transactions, Jiang directly owns 5,303,911 shares of Cytek Biosciences common stock and 141,377 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives who receive stock-based compensation. It provides transparency into the trading activities of company leadership.
Stakeholder Impact
- The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares upon RSU vesting.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of RSU vesting and tax withholding. |
| 03/13/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.